Delphia Therapeutics

0 followers


Delphia Therapeutics is a biotechnology company pioneering activation lethality, a new area of cancer therapeutics that target cancer's surprising vulnerability to oncogene overactivation. Delphia’s activation lethality platform offers the potential for first-in-class targeted cancer medicines that... Read more

Headquarters

Cambridge, US

Employees

11-50

Links

Org chart

Kevin Marks
President & CEO

Kevin Marks

Collapse
Aimee Usera
Vp, Head Of Chemistry
Michael Acker
Vice President, Biomolecular Sciences
Bryan Gutierrez
Vice President And Head Of Operations
Michael D.
Co-founder
Jill Parolin
Director, Human Resources
Stella Paffenholz
Board Observer

Teams

This company has no teams yet